---
title: "Viking Therapeutics (NASDAQ:VKTX) Posts  Earnings Results, Misses Estimates By $0.07 EPS"
description: "Viking Therapeutics (NASDAQ:VKTX) reported a quarterly EPS of ($0.41), missing estimates by $0.07. The stock traded up 1.4% to $25.84, with a market cap of $2.90 billion. Analysts have mixed ratings, "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/237449226.md"
published_at: "2025-04-24T20:32:17.000Z"
---

# Viking Therapeutics (NASDAQ:VKTX) Posts  Earnings Results, Misses Estimates By $0.07 EPS

> Viking Therapeutics (NASDAQ:VKTX) reported a quarterly EPS of ($0.41), missing estimates by $0.07. The stock traded up 1.4% to $25.84, with a market cap of $2.90 billion. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a target price of $89.75. Insider activity includes a purchase of 1,240 shares by Director Sarah Kathryn Rouan. The company focuses on developing therapies for metabolic disorders, with its lead candidate VK2809 in Phase IIb trials.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07), Zacks reports.

Get **Viking Therapeutics** alerts:

## Viking Therapeutics Trading Up 1.4 %

-   Viking Therapeutics Stock Pops But Struggles to Hold Gains

VKTX traded up $0.36 during trading on Wednesday, hitting $25.84. 4,145,398 shares of the company's stock were exchanged, compared to its average volume of 4,045,729. The stock has a 50 day moving average price of $26.75 and a 200 day moving average price of $41.30. Viking Therapeutics has a 1 year low of $18.92 and a 1 year high of $81.86. The firm has a market cap of $2.90 billion, a P/E ratio of -25.84 and a beta of 0.84.

## Wall Street Analyst Weigh In

VKTX has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $102.00 target price on shares of Viking Therapeutics in a research report on Thursday, April 17th. The Goldman Sachs Group began coverage on shares of Viking Therapeutics in a report on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 price target on the stock. B. Riley reiterated a "buy" rating and set a $96.00 target price (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. Scotiabank began coverage on Viking Therapeutics in a research note on Thursday, February 13th. They set a "sector outperform" rating and a $102.00 price objective on the stock. Finally, Maxim Group reduced their target price on shares of Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $89.75.

-   Which Healthcare Stock Is the Best Buy Right Now?

**Get Our Latest Stock Analysis on Viking Therapeutics**

## Insider Activity at Viking Therapeutics

In other news, Director Sarah Kathryn Rouan purchased 1,240 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average price of $24.15 per share, with a total value of $29,946.00. Following the purchase, the director now directly owns 1,240 shares of the company's stock, valued at approximately $29,946. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.70% of the stock is owned by insiders.

## About Viking Therapeutics

(Get Free Report)

-   MarketBeat Week in Review – 03/17 - 03/21

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

## Read More

-   Five stocks we like better than Viking Therapeutics
-   Are Penny Stocks a Good Fit for Your Portfolio?
-   Can IBM’s Q1 Earnings Spark a Breakout for the Stock?
-   What is a Low P/E Ratio and What Does it Tell Investors?
-   S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry?
-   Where to Find Earnings Call Transcripts
-   Fundamentally Sound, These 5 Stocks Sold Off Anyway

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Viking Therapeutics Right Now?

Before you consider Viking Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.

While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [VKTX.US - Viking Therap](https://longbridge.com/en/quote/VKTX.US.md)
- [VIK.US - Viking](https://longbridge.com/en/quote/VIK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BUZZ-Viking 治疗公司股价上涨，因其计划在后期研究中测试口服肥胖药物 | Viking Therapeutics 的股票上涨了 9.4%，至 31.24 美元，此前该公司宣布计划在第三季度将其口服肥胖药 VK2735 推进至后期试验。VKTX 强调提供口服和注射两种剂型的重要性，因为目前没有其他双重或三重激动剂同 | [Link](https://longbridge.com/en/news/275665780.md) |
| Viking Therapeutics 公布 2025 财年的研究与开发费用为 3.45 亿美元 | Viking Therapeutics Inc. 报告其 2025 财年的研发费用为 3.45 亿美元，未产生任何收入，因为尚未商业化任何药物候选者。这些费用因 VK2735 和 VK2809 的临床试验而显著增加。公司在其产品线方面取得了 | [Link](https://longbridge.com/en/news/275668350.md) |
| Viking CEO 表示，减肥交易的需求比表面上看到的更为广泛 | Viking Therapeutics 首席执行官 Brian Lian 表示，对减肥药物交易的兴趣比看起来更广泛，因为制药公司旨在进入预计达到 1500 亿美元的市场。关键的增长因素包括扩展的临床应用和下一代疗法。Lian 指出，公司正在 | [Link](https://longbridge.com/en/news/272335070.md) |
| Viking 治疗在最新的公司展示中展示了其在肥胖和代谢疾病领域的研发进展 | Viking Therapeutics Inc. 发布了一份企业演示文稿，重点介绍其在代谢和内分泌疾病领域的管线进展。值得注意的更新包括正在进行的 VK2735 的第三阶段 VANQUISH 计划，这是一种用于肥胖的双重 GLP-1/GIP | [Link](https://longbridge.com/en/news/272603256.md) |
| Viking 治疗公司报告称，第二阶段试验结果显示，VK2735 在肥胖患者中实现了最高 14.7% 的体重减轻 | Viking Therapeutics Inc. 报告称，其 VK2735 的第二阶段 VENTURE 试验显示，在 13 周后，肥胖患者的体重减轻高达 14.7%，且结果没有出现平台期。该治疗耐受性良好，主要的不良事件为轻度或中度。VK2 | [Link](https://longbridge.com/en/news/272265172.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
